Literature DB >> 17109465

Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma.

Taku Fujimura1, Satoshi Nakagawa, Tomoyuki Ohtani, Yumiko Ito, Setsuya Aiba.   

Abstract

Cellular proteins, retinoic acid inducible gene-I and Toll-like receptor 3, sense dsRNA including polyinosinic-polycytidylic acid (PIC) to stimulate innate immune response. The local administration of PIC has been demonstrated to be effective in anti-tumor immunotherapy. However, the effects of PIC delivered cross the cell membrane have not yet been examined. To address this issue, we used a complex of PIC and cationic liposome (PIC liposome) and examined its anti-tumor effects in vitro and in vivo. PIC liposome could directly suppress the growth of B16F10 melanoma in vitro and repeated peritumoral injections of PIC liposome inhibited melanoma growth in a dose-dependent manner. This treatment induced tyrosinase-related protein-2 (TRP-2)-tetramer(+) CD8(+) cells in the lymph nodes. As the mechanism for its anti-tumor immune response, we showed that the intradermal injection of PIC liposome induced the maturation of dendritic cells (DC). Moreover, the intratumoral injection of immature DC after treatment with PIC liposome significantly increased the number of TRP-2-specific IFN-gamma-producing cells in the lymph nodes as well as spleen, which resulted in an augmentation of the anti-tumor immune response. These studies demonstrate the potential of peritumoral injection of PIC liposome as immunotherapy for malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109465     DOI: 10.1002/eji.200636053

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  Control of solid tumor growth in mice using EGF receptor-targeted RNA replicase-based plasmid DNA.

Authors:  B Leticia Rodriguez; Xinran Li; Kaoru Kiguchi; John DiGiovanni; Evan C Unger; Zhengrong Cui
Journal:  Nanomedicine (Lond)       Date:  2012-02-02       Impact factor: 5.307

Review 2.  Liposome-nucleic acid immunotherapeutics.

Authors:  Steven Dow
Journal:  Expert Opin Drug Deliv       Date:  2008-01       Impact factor: 6.648

Review 3.  Engineering nanomedicines for improved melanoma therapy: progress and promises.

Authors:  Di Bei; Jianing Meng; Bi-Botti C Youan
Journal:  Nanomedicine (Lond)       Date:  2010-11       Impact factor: 5.307

4.  EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice.

Authors:  Alexei Shir; Manfred Ogris; Wolfgang Roedl; Ernst Wagner; Alexander Levitzki
Journal:  Clin Cancer Res       Date:  2010-12-30       Impact factor: 12.531

5.  Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity.

Authors:  Corbin Clawson; Chien-Tze Huang; Diahnn Futalan; Daniel Martin Seible; Rebecca Saenz; Marie Larsson; Wenxue Ma; Boris Minev; Fiona Zhang; Mihri Ozkan; Cengiz Ozkan; Sadik Esener; Davorka Messmer
Journal:  Nanomedicine       Date:  2010-03-27       Impact factor: 5.307

6.  Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells.

Authors:  Damià Tormo; Agnieszka Checińska; Direna Alonso-Curbelo; Eva Pérez-Guijarro; Estela Cañón; Erica Riveiro-Falkenbach; Tonantzin G Calvo; Lionel Larribere; Diego Megías; Francisca Mulero; Miguel A Piris; Rupesh Dash; Paola M Barral; José L Rodríguez-Peralto; Pablo Ortiz-Romero; Thomas Tüting; Paul B Fisher; María S Soengas
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

7.  Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity.

Authors:  Uyen M Le; Darryl G L Kaurin; Brian R Sloat; Nijaporn Yanasarn; Zhengrong Cui
Journal:  Radiother Oncol       Date:  2008-11-14       Impact factor: 6.280

Review 8.  In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.

Authors:  Linda Hammerich; Adam Binder; Joshua D Brody
Journal:  Mol Oncol       Date:  2015-11-10       Impact factor: 6.603

9.  Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.

Authors:  B Leticia Rodriguez; Jorge M Blando; Dharmika S P Lansakara-P; Yuriko Kiguchi; John DiGiovanni; Zhengrong Cui
Journal:  Mol Pharm       Date:  2013-05-17       Impact factor: 4.939

Review 10.  Roles of Toll-Like Receptor 3 in Human Tumors.

Authors:  Xin Zheng; Song Li; Hui Yang
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.